Compare BX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BX | BMY |
|---|---|---|
| Founded | 1985 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.4B | 123.7B |
| IPO Year | 2007 | N/A |
| Metric | BX | BMY |
|---|---|---|
| Price | $114.64 | $58.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 16 |
| Target Price | ★ $161.73 | $62.13 |
| AVG Volume (30 Days) | 6.7M | ★ 9.9M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | 4.05% | ★ 4.24% |
| EPS Growth | ★ 6.91 | N/A |
| EPS | ★ 3.87 | N/A |
| Revenue | ★ $14,450,265,000.00 | N/A |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $21.79 | N/A |
| P/E Ratio | $30.28 | ★ $17.26 |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $101.73 | $42.52 |
| 52 Week High | $190.09 | $62.89 |
| Indicator | BX | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 46.95 |
| Support Level | $104.00 | $56.45 |
| Resistance Level | $115.98 | $62.39 |
| Average True Range (ATR) | 4.07 | 1.27 |
| MACD | 1.39 | -0.06 |
| Stochastic Oscillator | 62.92 | 36.45 |
Blackstone is the world's largest alternative-asset manager with $1.242 trillion in total asset under management, including $906.2 billion in fee-earning assets under management, at the end of September 2025. The company operates with scale in each of its major product lines: private equity (26% of fee-earning AUM and 33% of base management fees), real estate/real assets (31% and 35%), private credit (34% and 25%), and other alternatives (9% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.